Quick answers
- What is Enalapril maleate and hydrochlorothiazide used for?
- The FDA-approved label (Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., July 14, 2026) says: “Enalapril maleate and hydrochlorothiazide is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Enalapril maleate and hydrochlorothiazide?
- The “Adverse Reactions” section of the FDA label (Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., July 14, 2026) begins: “Enalapril maleate and hydrochlorothiazide has been evaluated for safety in more than 1500 patients, including over 300 patients treated for one year or more. In clinical trials with enalapril maleate and hydrochlorothiazide no adverse experiences peculiar to this combination drug have been observed. Adverse experiences that have occurred, have been limited to those that have been previously reported with enalapril or hydrochlorothiazide.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Enalapril maleate and hydrochlorothiazide?
- The “Drug Interactions” section of the FDA label (Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., July 14, 2026) begins: “Neprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema (see WARNINGS). Enalapril Maleate Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Enalapril maleate and hydrochlorothiazide have a boxed warning?
- Yes. The FDA label for Enalapril Maleate and Hydrochlorothiazide has a boxed warning (“WARNING: FETAL TOXICITY”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Enalapril maleate and hydrochlorothiazide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Enalapril maleate and hydrochlorothiazide been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started May 21, 2014 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Enalapril maleate and hydrochlorothiazide?
- 3 companies list prescription products of Enalapril maleate and hydrochlorothiazide in the FDA NDC Directory, including Dr. Reddy's Laboratories Limited, Sun Pharmaceutical Industries, Inc. and Bausch Health US, LLC.
What Enalapril maleate and hydrochlorothiazide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Enalapril maleate and hydrochlorothiazide is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). …
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (tablet, oral), Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc.; it covers 2 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 3 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: FETAL TOXICITY
. Read it on the full label →
3 of 3 FDA labels for this medicine have a boxed warning.
Enalapril maleate and hydrochlorothiazide boxed warning: what the label says
Quoted from the boxed warning of the FDA-approved label.
WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue enalapril maleate and hydrochlorothiazide as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. Read the full label on DailyMed →
Enalapril maleate and hydrochlorothiazide side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
Enalapril maleate and hydrochlorothiazide has been evaluated for safety in more than 1500 patients, including over 300 patients treated for one year or more. In clinical trials with enalapril maleate and hydrochlorothiazide no adverse experiences peculiar to this combination drug have been observed. Adverse experiences that have occurred, have been limited to those that have been previously reported with enalapril or hydrochlorothiazide.
Read more of this section
The most frequent clinical adverse experiences in controlled trials were: dizziness (8.6 percent), headache (5.5 percent), fatigue (3.9 percent) and cough (3.5 percent). Generally, adverse experiences were mild and transient in nature. Adverse experiences occurring in greater than two percent of patients treated with enalapril maleate and hydrochlorothiazide in controlled clinical trials are shown below. Percent of Patients in Controlled Studies Enalapril maleate and hydrochlorothiazide (n=1580) Incidence (discontinuation) Placebo (n=230) Incidence Dizziness 8.6 (0.7) 4.3 Headache 5.5 (0.4) 9.1 Fatigue 3.9 (0.8) 2.6 Cough 3.5 (0.4) 0.9 Muscle Cramps 2.7 (0.2) 0.9 Nausea 2.5 (0.4) 1.7 Asthenia 2.4 (0.3) 0.9 Orthostatic Effects 2.3 (<0.1) 0.0 Impotence 2.2 (0.5) 0.5 Diarrhea 2.1 (<0.1) 1.7 Clinical adverse experiences occurring in 0.5 to 2.0 percent of patients in controlled trials included: Body As A Whole: Syncope, chest pain, abdominal pain Cardiovascular: Orthostatic hypotension, palpitation, tachycardia Digestive: Vomiting, dyspepsia, constipation, flatulence, dry mouth Nervous/Psychiatric: Insomnia, nervousness, paresthesia, somnolence, vertigo Skin: Pruritus, rash Other: Dyspnea, gout, back pain, arthralgia, diaphoresis, decreased libido, tinnitus, urinary tract infection Angioedema: Angioedema has been reported in patients receiving enalapril maleate and hydrochlorothiazide, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalapril maleate and hydrochlorothiazide should be discontinued and appropriate therapy instituted immediately (see WARNINGS). Hypotension: In clinical trials, adverse effects relating to hypotension occurred as follows: hypotension (0.9 percent), orthostatic hypotension (1.5 percent), other orthostatic effects (2.3 percent). In addition syncope occurred in 1.3 percent of patients (see WARNINGS). Cough: See PRECAUTIONS, Cough. Clinical Laboratory Test Findings Serum Electrolytes: See PRECAUTIONS. Creatinine, Blood Urea Nitrogen: In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.6 percent of patients with essential hypertension treated with enalapril maleate and hydrochlorothiazide. More marked increases have been reported in other enalapril experience. Increases are more likely to occur in patients with renal artery stenosis (see PRECAUTIONS). Serum Uric Acid, Glucose, Magnesium, and Calcium: See PRECAUTIONS.
Table from the label
| Percent of Patients in Controlled Studies | ||
|---|---|---|
| Enalapril maleate and hydrochlorothiazide (n=1580) Incidence (discontinuation) | Placebo (n=230) Incidence | |
| Dizziness | 8.6 (0.7) | 4.3 |
| Headache | 5.5 (0.4) | 9.1 |
| Fatigue | 3.9 (0.8) | 2.6 |
| Cough | 3.5 (0.4) | 0.9 |
| Muscle Cramps | 2.7 (0.2) | 0.9 |
| Nausea | 2.5 (0.4) | 1.7 |
| Asthenia | 2.4 (0.3) | 0.9 |
| Orthostatic Effects | 2.3 (<0.1) | 0.0 |
| Impotence | 2.2 (0.5) | 0.5 |
| Diarrhea | 2.1 (<0.1) | 1.7 |
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. This is part of the section. Read the full label on DailyMed →
Enalapril maleate and hydrochlorothiazide drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Neprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema (see WARNINGS). Enalapril Maleate Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Read more of this section
Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on enalapril maleate and hydrochlorothiazide and other agents that affect the RAS. Do not coadminister aliskiren with enalapril maleate and hydrochlorothiazide in patients with diabetes. Avoid use of aliskiren with enalapril maleate and hydrochlorothiazide in patients with renal impairment (GFR <60 mL/min). Hypotension – Patients on Diuretic Therapy Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS and DOSAGE AND ADMINISTRATION). Agents Causing Renin Release The antihypertensive effect of enalapril is augmented by antihypertensive agents that cause renin release (e.g., diuretics). Non-steroidal Anti-inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving enalapril and NSAID therapy. In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. Other Cardiovascular Agents Enalapril has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium Enalapril attenuates diuretic-induced potassium loss. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. This is part of the section. Read the full label on DailyMed →
Enalapril maleate and hydrochlorothiazide dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Enalapril and hydrochlorothiazide are effective treatments for hypertension. The usual dosage range of enalapril is 10 to 40 mg per day administered in a single or two divided doses; hydrochlorothiazide is effective in doses of 12.5 to 50 mg daily.
Read more of this section
The side effects (see WARNINGS) of enalapril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of enalapril and hydrochlorothiazide will be associated with both sets of dose-independent side effects but the addition of enalapril in clinical trials blunted the hypokalemia normally seen with diuretics. To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either enalapril or hydrochlorothiazide monotherapy may be given enalapril maleate and hydrochlorothiazide 5/12.5 mg or enalapril maleate and hydrochlorothiazide 10/25 mg. Further increases of enalapril, hydrochlorothiazide or both depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2 to 3 weeks have elapsed. In general, patients do not require doses in excess of 20 mg of enalapril or 50 mg of hydrochlorothiazide. The daily dosage should not exceed four tablets of enalapril maleate and hydrochlorothiazide 5/12.5 mg or two tablets of enalapril maleate and hydrochlorothiazide 10/25 mg. Replacement Therapy The combination may be substituted for the titrated components. Use in Renal Impairment The usual regimens of therapy with enalapril maleate and hydrochlorothiazide need not be adjusted as long as the patient's creatinine clearance is greater than 30 mL/min/1.73m2 (serum creatinine approximately less than or equal to 3 mg/dL or 265 μmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so enalapril maleate and hydrochlorothiazide is not recommended (see WARNINGS, Anaphylactoid Reactions During Membrane Exposure).
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. Read the full label on DailyMed →
Enalapril maleate and hydrochlorothiazide and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
Enalapril, enalaprilat, and hydrochlorothiazide have been detected in human breast milk. Because of the potential for serious reactions in nursing infants from either drug, a decision should be made whether to discontinue nursing or to discontinue enalapril maleate and hydrochlorothiazide, taking into account the importance of the drug to the mother.
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. Read the full label on DailyMed →
When Enalapril maleate and hydrochlorothiazide should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
Read more of this section
Enalapril maleate and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate and hydrochlorothiazide within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS). Do not co-administer aliskiren with enalapril maleate and hydrochlorothiazide in patients with diabetes (see PRECAUTIONS, Drug Interactions).
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. Read the full label on DailyMed →
Enalapril maleate and hydrochlorothiazide overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
No specific information is available on the treatment of overdosage with enalapril maleate and hydrochlorothiazide. Treatment is symptomatic and supportive. Therapy with enalapril maleate and hydrochlorothiazide should be discontinued and the patient observed closely. Suggested measures include induction of emesis and/or gastric lavage, and correction of dehydration, electrolyte imbalance and hypotension by established procedures.
Read more of this section
Enalapril Maleate Single oral doses of enalapril above 1,000 mg/kg and ≥ 1,775 mg/kg were associated with lethality in mice and rats, respectively. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution. Enalaprilat may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis (see WARNINGS, Anaphylactoid Reactions During Membrane Exposure). Hydrochlorothiazide Lethality was not observed after administration of an oral dose of 10 g/kg to mice and rats. The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.
— FDA label: Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 5 in the FDA NDC Directory |
| Brand names | Vaseretic |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| enalapril maleate 10 mg · hydrochlorothiazide 25 mg tablet | Generic | $0.2446 per tablet |
| enalapril maleate 5 mg · hydrochlorothiazide 12.5 mg tablet | Generic | $0.1791 per tablet |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Dr. Reddy's Laboratories Limited2 products
- Sun Pharmaceutical Industries, Inc.2 products
- Bausch Health US, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA019221 VASERETIC | Bausch | October 31, 1986 | 37, latest August 20, 2020 2020: Labeling · 2017: Labeling · 2015: Labeling |
Generic approvals (2)
- ANDA075788Taro Pharm Inds · September 18, 2001
- ANDA075909Pharmazone · October 15, 2001
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
May 21, 2014 · Class III · Terminated · D-0018-2015
Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package outset
Vaseretic (enalapril maleate/hydrochlorothiazide) 10/25 mg Tablets, NDC 0187-0146-01, 100 ct. bottles manufactured at Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada — Valeant Pharmaceuticals North America LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 858824, 858828, 858830 |
|---|---|
| SPL set ID of the quoted label | 7cb92cf2-46f2-4379-937c-168d230e43a4 |
| FDA labels (SPL) | 3 |
| FDA applications | NDA019221, 2 ANDA |
| Active ingredients (FDA) | ENALAPRIL / HYDROCHLOROTHIAZIDE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- VasereticBrand page: products, maker and price
- High blood pressureCondition named on the label: hospitals that treat it
- Dr. Reddy's Laboratories LimitedMaker or distributor
- Sun Pharmaceutical Industries, Inc.Maker or distributor
- Bausch Health US, LLCMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Enalapril Maleate and Hydrochlorothiazide, Sun Pharmaceutical Industries, Inc., effective July 14, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →